Literature DB >> 15585388

Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma.

Hidekazu Kuramochi1, Daniel Vallböhmer, Kazumi Uchida, Sylke Schneider, Nahid Hamoui, Daisuke Shimizu, Parakrama T Chandrasoma, Tom R DeMeester, Kathleen D Danenberg, Peter V Danenberg, Jeffrey H Peters.   

Abstract

Cyclooxygenase (Cox-2) is implicated in the pathogenesis of many cancers including esophageal adenocarcinoma (EAC), whereas the role of the isoform Cox-1 in carcinogenesis is not well understood. To further elucidate the role of these factors in the development of EAC, we measured the gene expressions (mRNA levels) of Cox-2 and Cox-1 by real-time quantitative polymerase chain reaction (QRT-PCR) in tissues from normal esophagus with and without erosive gastroesophageal reflux disease (GERD), Barrett's esophagus (BE), dysplasia, adenocarcinoma, and in healthy gastric antrum. All tissues were purified by laser capture microdissection from endoscopic or surgical resection specimens. Median Cox-2 gene expression did not differ significantly among the esophageal control groups but was elevated 5-fold in BE, 8-fold in dysplasia and 16-fold in EAC compared to normal esophageal controls with no erosive GERD. Erosive GERD tissue had slightly higher median Cox-2 expression but Cox-2 expression in normal antrum was much higher than that in a normal esophagus, close to that of dysplasia. In contrast to that of Cox-2, Cox-1 expression was significantly decreased in all neoplastic tissues compared to normal controls. Cox-1 and Cox-2 expression varied over a wide range in the neoplastic tissues but over a relatively narrow range in the esophageal normal tissues. The occurrence of substantial alterations in Cox-1 and Cox-2 expression at the BE stage indicates that these are early events in the development of EAC. These results confirm the important role of Cox-2 amplification in the pathogenesis of esophageal adenocarcinoma, but the unexpected down-regulation of Cox-1 raises questions about its role in carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15585388     DOI: 10.1016/j.gassur.2004.09.025

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  33 in total

Review 1.  Barrett's esophagus.

Authors:  Jeffrey H Peters; Jeffrey A Hagen; Steven R DeMeester
Journal:  J Gastrointest Surg       Date:  2004-01       Impact factor: 3.452

2.  Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure.

Authors:  V N Shirvani; R Ouatu-Lascar; B S Kaur; M B Omary; G Triadafilopoulos
Journal:  Gastroenterology       Date:  2000-03       Impact factor: 22.682

3.  Real time quantitative PCR.

Authors:  C A Heid; J Stevens; K J Livak; P M Williams
Journal:  Genome Res       Date:  1996-10       Impact factor: 9.043

4.  Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus.

Authors:  M K Hong; W B Laskin; B E Herman; M H Johnston; J J Vargo; S M Steinberg; C J Allegra; P G Johnston
Journal:  Cancer       Date:  1995-01-15       Impact factor: 6.860

Review 5.  Barrett's esophagus.

Authors:  S J Spechler
Journal:  Semin Oncol       Date:  1994-08       Impact factor: 4.929

Review 6.  Distinct functions of COX-1 and COX-2.

Authors:  Ikuo Morita
Journal:  Prostaglandins Other Lipid Mediat       Date:  2002-08       Impact factor: 3.072

7.  The role of retinoid X receptor messenger RNA expression in curatively resected non-small cell lung cancer.

Authors:  Jan Brabender; Kathleen D Danenberg; Ralf Metzger; Paul M Schneider; Reginald V Lord; Susan Groshen; Denice D Tsao-Wei; JiMin Park; Dennis Salonga; Arnulf H Hölscher; Peter V Danenberg
Journal:  Clin Cancer Res       Date:  2002-02       Impact factor: 12.531

8.  Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action.

Authors:  Chris Tselepis; Ian Perry; Chris Dawson; Rob Hardy; S Jane Darnton; Chris McConkey; Rob C Stuart; Nick Wright; Rebecca Harrison; Janusz Antoni Z Jankowski
Journal:  Oncogene       Date:  2002-09-05       Impact factor: 9.867

9.  Aspirin and reduced risk of esophageal carcinoma.

Authors:  E M Funkhouser; G B Sharp
Journal:  Cancer       Date:  1995-10-01       Impact factor: 6.860

Review 10.  Cyclooxygenase-2 biology.

Authors:  Joan Clària
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

View more
  11 in total

1.  Biomarkers in exploring the frontiers of diagnosis, prognosis, and therapy of Barrett's esophagus.

Authors:  Patrick Yachimski; Richard M Peek
Journal:  Cancer Prev Res (Phila)       Date:  2011-06

2.  Large intra- and inter-individual variability of genes expression levels limits potential predictive value of molecular diagnosis of dysplasia in Barrett's esophagus.

Authors:  Ewa E Hennig; Michal Mikula; Janina Orlowska; Dorota Jarosz; Andrzej Bielasik; Jaroslaw Regula; Jerzy Ostrowski
Journal:  J Mol Med (Berl)       Date:  2007-10-19       Impact factor: 4.599

3.  Towards the molecular characterization of disease: comparison of molecular and histological analysis of esophageal epithelia.

Authors:  Daniel Vallböhmer; Paul Marjoram; Hidekazu Kuramochi; Daisuke Shimizu; Hsuan Jung; Steve R DeMeester; Daniel Oh; Parakrama T Chandrasoma; Kathleen D Danenberg; Tom R DeMeester; Peter V Danenberg; Jeffrey H Peters
Journal:  J Gastrointest Surg       Date:  2007-09       Impact factor: 3.452

4.  Cox2 and β-catenin/T-cell factor signaling intestinalize human esophageal keratinocytes when cultured under organotypic conditions.

Authors:  Jianping Kong; Mary Ann S Crissey; Douglas B Stairs; Antonia R Sepulveda; John P Lynch
Journal:  Neoplasia       Date:  2011-09       Impact factor: 5.715

5.  Cyclooxygenase-2 expression in esophageal epithelium before and after photodynamic therapy for Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma.

Authors:  Patrick Yachimski; Mari Mino-Kenudson; Margaret E Sherwood; William P Puricelli; Norman S Nishioka; Gregory Y Lauwers
Journal:  Virchows Arch       Date:  2011-11-13       Impact factor: 4.064

6.  MicroRNA-196a & microRNA-101 expression in Barrett's oesophagus in patients with medically and surgically treated gastro-oesophageal reflux.

Authors:  Sebastien Haiart; David I Watson; Mary P Leong; David Astill; Tim Bright; Damian J Hussey
Journal:  BMC Res Notes       Date:  2011-02-27

7.  COX-2 mRNA expression is significantly increased in acid-exposed compared to nonexposed squamous epithelium in gastroesophageal reflux disease.

Authors:  Georg Lurje; Daniel Vallbohmer; Peter H Collet; Huan Xi; Stephan E Baldus; Jan Brabender; Ralf Metzger; Michaela Heitmann; Susanne Neiss; Ute Drebber; Arnulf H Holscher; Paul M Schneider
Journal:  J Gastrointest Surg       Date:  2007-07-10       Impact factor: 3.452

8.  Intramucosal distribution of WNT signaling components in human esophagus.

Authors:  Irshad Ali; Parvaneh Rafiee; Yue Zheng; Christopher Johnson; Banani Banerjee; George Haasler; Howard Jacob; Reza Shaker
Journal:  J Clin Gastroenterol       Date:  2009-04       Impact factor: 3.062

9.  Loss of heterozygosity at thymidylate synthase locus in Barrett's metaplasia, dysplasia, and carcinoma sequences.

Authors:  Hidekazu Kuramochi; Kazumi Uchida; Jeffery H Peters; Daisuke Shimizu; Daniel Vallbohmer; Sylke Schneider; Kathleen D Danenberg; Peter V Danenberg
Journal:  BMC Cancer       Date:  2009-05-21       Impact factor: 4.430

Review 10.  Melatonin in Prevention of the Sequence from Reflux Esophagitis to Barrett's Esophagus and Esophageal Adenocarcinoma: Experimental and Clinical Perspectives.

Authors:  Jolanta Majka; Mateusz Wierdak; Iwona Brzozowska; Marcin Magierowski; Aleksandra Szlachcic; Dagmara Wojcik; Slawomir Kwiecien; Katarzyna Magierowska; Jacek Zagajewski; Tomasz Brzozowski
Journal:  Int J Mol Sci       Date:  2018-07-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.